Middle molecular uremic substances retention itself might influence the bioincompatibility of PD solution  by Yokoyama, Keitaro et al.
Middle molecular uremic
substances retention itself might
influence the bioincompatibility of
PD solution
Kidney International (2008) 74, 822; doi:10.1038/ki.2008.283
To the Editor: It was demonstrated that a higher peritoneal
membrane solute transport rate is associated with a higher
mortality risk and a trend to higher technique failure.1 It has
been suggested that the bioincompatible nature of conven-
tional peritoneal dialysis (PD) solutions contributes to the
structural peritoneal membrane changes that lead to
deterioration in solute transport characteristics and loss of
ultrafiltration.2
However, Fan et al.3 reported that the clinical outcomes
(residual kidney function, peritoneal membrane function,
technique survival, and peritonitis rates) were the same,
irrespective of standard or biocompatible PD solutions.
In the HEMO dialysis study, it became apparent that serum
b2 microglobulin (b2M) levels, not KT/V, were the strong
predictors of mortality.4 It was reported that the clearance of
b2M by hemodialysis (when high-flux membranes were used)
was higher than that by PD.5
We stained peritoneal tissue from continuous ambulatory
peritoneal dialysis (CAPD) patients (n¼ 19) for b2M (rabbit
anti-human b2M; DAKO, Glostrup, Denmark). In almost all
the patients, deposits of b2M were found in the compact zone
(Figure 1). We previously investigated the associations of
b2M clearance with PD and residual renal function, and
serum b2M levels with duration of dialysis in 20 subjects on
continuous ambulatory peritoneal dialysis and found that
serum b2M levels increased with duration of dialysis. As for
b2M clearance by residual renal function per se, it was
significantly lower in subjects with long duration of dialysis
even though no difference was observed in the total daily
b2M clearance.
6 We also reported that b2M is useful as a
screening test for the onset of encapsulating peritoneal
sclerosis and that the accumulation of both b2M and middle
molecular uremic substances may be related to the patho-
physiology of encapsulating peritoneal sclerosis.7
b2 Microglobulin may have a pathogenic role, which
is unproven; however still, if middle molecular uremic
substance retention itself influences the bioincompatibility
of PD solution, it might be worthwhile to attempt combined
continuous ambulatory peritoneal dialysis and hemodialysis
treatment in patients with high b2M levels for whom
sufficient clearance cannot be maintained with continuous
ambulatory peritoneal dialysis alone, but this also requires
further study. We should not pay attention only to PD
solution but also to middle molecular uremic substance
retention.
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Figure 1 | b2M staining in peritoneal tissue from CAPD
patients.
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